#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ovarian cancer stage III Pancreatic carcinoma metastatic Heritable pulmonary arterial hypertension Primary amyloidosis Small intestine neuroendocrine tumour Andersen-Tawil syndrome Lung adenocarcinoma Transplant rejection Anti-myelin-associated glycoprotein antibodies positive Neuromyelitis optica spectrum disorder Thrombotic microangiopathy Adenoid cystic carcinoma Autoimmune disorder Spinal muscular atrophy Lennox-Gastaut syndrome More trials…

    Learn about Rare Diseases

    Niemann-Pick disease – Treatment Niemann-Pick disease – Diagnostics Mucous membrane pemphigoid – Trials in Disease Niemann-Pick disease – Life with Disease Noonan syndrome – Life with Disease Glycogen storage disease type I – Diagnostics Haemophagocytic lymphohistiocytosis – Trials in Disease Glycogen storage disease type I – Trials in Disease Chordoma Haemophilia B with anti factor IX – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Deucrictibant Cebsulfase Alfa Phosphocreatine Sodium Calcium Polystyrene Sulfonate Efpegerglucagon Bisoprolol Milrinone Cpk850 Cedazuridine Bi 1291583 Sorafenib Tosilate Methoxyflurane Gd2Il18Cart IMEROPRUBART Tafamidis SODIUM BENZOATE Nimorazole Azd8421 Pazopanib Human Coagulation Factor Ii More therapies…

    Learn about Your Condition

    Spinal cord injury Prostate cancer recurrent Urticaria chronic Plasmablastic lymphoma Still's disease Papillary thyroid cancer Neurofibromatosis Exfoliation glaucoma Langerhans cell sarcoma Cardiac failure chronic Thrombocytopenia Prinzmetal angina Vaginal cancer Shprintzen-Goldberg syndrome Tendon disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hopital Tenon

Hopital Tenon

4 Rue De La Chine, Paris, 75970, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 mutant non-small cell lung cancer
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Pembrolizumab
    Belgium France Germany Greece Italy Poland +3

  • Study of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Head and neck cancer
    Investigated Drugs:
    • HAFNIUM OXIDE
    • Cetuximab
    Austria Belgium Czechia France Germany Greece +4

  • Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Tepotinib
    • Vinorelbine
    • Atezolizumab
    France

  • Evaluation of remibrutinib (LOU064) effectiveness and safety in adult patients with chronic urticaria: A 12-week placebo-controlled study

    Recruiting

    2 1 1
    Investigated Diseases:
    • Urticaria chronic
    Investigated Drugs:
    • Remibrutinib
    France Germany Poland Spain

  • Study on the Safety and Effects of BMS-986507 with Pembrolizumab and Osimertinib Mesylate in Adults with Advanced Solid Tumors

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • OSIMERTINIB MESYLATE
    • Pembrolizumab
    France Italy The Netherlands Spain

  • Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • Carboplatin
    • Cemiplimab
    • Paclitaxel
    France

  • Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Anastrozole
    • Elacestrant
    • Exemestane
    Austria Belgium Czechia Denmark Finland France +9

  • Study Comparing Doravirine/Lamivudine and Dolutegravir/Lamivudine for HIV Patients with Controlled Viral Load on Three-Drug Regimens

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Dolutegravir
    • Doravirine
    • Lamivudine
    France

  • Study on Cabozantinib and Nivolumab for Older Patients with Kidney Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cabozantinib
    • Nivolumab
    France

  • Study of Ketamine Alone and Ketamine-Propofol Combination Compared to Propofol for Rapid Sequence Induction in Operating Room Patients at Risk of Aspiration

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ketamine
    • Propofol
    France
Previous Page
1 2 3 4 … 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!